Contineum Therapeutics (CTNM) Enterprise Value: 2023-2025
Historic Enterprise Value for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $147.1 million.
- Contineum Therapeutics' Enterprise Value fell 47.17% to $147.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$423.9 million, marking a year-over-year decrease of 131.22%. This contributed to the annual value of $172.9 million for FY2024, which is 238.10% up from last year.
- As of Q3 2025, Contineum Therapeutics' Enterprise Value stood at $147.1 million, which was up 302.11% from -$72.8 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Enterprise Value registered a high of $278.4 million during Q3 2024, and its lowest value of -$125.2 million during Q4 2023.
- In the last 3 years, Contineum Therapeutics' Enterprise Value had a median value of $68.5 million in 2025 and averaged $63.3 million.
- In the last 5 years, Contineum Therapeutics' Enterprise Value spiked by 238.10% in 2024 and then crashed by 131.06% in 2025.
- Contineum Therapeutics' Enterprise Value (Quarterly) stood at -$125.2 million in 2023, then skyrocketed by 238.10% to $172.9 million in 2024, then plummeted by 47.17% to $147.1 million in 2025.
- Its last three reported values are $147.1 million in Q3 2025, -$72.8 million for Q2 2025, and -$10.1 million during Q1 2025.